The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line

Research in Veterinary Science

Volumn 88, Issue 1, 2010, Pages 94-100

  Wolfesberger, B ^a   Tonar, Z ^b,c   Gerner, W ^a   Skalicky, M ^a   Heiduschka, G ^d   Egerbacher, M ^a   Thalhammer, J G ^a   Walter, I ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF WEST BOHEMIA   (Czech Republic)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Canine osteosarcoma; Carboplatin; Sorafenib

Indexed keywords

CARBOPLATIN; CASPASE 3; KI 67 ANTIGEN; SORAFENIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG MECHANISM; ENZYME ACTIVATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BONE NEOPLASMS; CASPASE 3; CELL COUNT; CELL LINE, TUMOR; DOG DISEASES; DOGS; FLOW CYTOMETRY; KI-67 ANTIGEN; MICROSCOPY, ELECTRON, TRANSMISSION; OSTEOSARCOMA; PROTEIN-TYROSINE KINASES; PYRIDINES;

CANIS FAMILIARIS;

EID: 71649083215     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2009.06.009     Document Type: Article

References (28)

1. Berthold D.R., and Moore M.J. Novel targets in prostate cancer. Expert Opinion on Therapeutic Targets 10 (2006) 777-780
2. Chang Y.S., Adnane J., Trail P.A., Levy J., Henderson A., Xue D., Bortolon E., Ichetovkin M., Chen C., McNabola A., Wilkie D., Carter C.A., Taylor I.C., Lynch M., and Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularisation and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemotherapy and Pharmacology 59 (2007) 561-574
3. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Review 58 3 (2006) 621-681
4. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., and Cooper C. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
5. Dernell, W.S., Ehrhart, N.P., Straw, R.C., Vail, D.M., 2007. Tumors of the skeletal system. In: Withrow and MacEwen's Small Animal Clinical Oncology, fourth ed. Saunders, pp. 540-572.
6. Escudier B., Eisen T., Stadler W.M., Szcyclik C., Oudard S., Siebles M., Negrier S., Chevreau C., Solska E., Desai A.A., Rollandi F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M., and TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine 356 (2007) 125-134
7. Gaver R.C., George A.M., Duncan G.F., Morris A.D., Deeb G., Faulkner H.C., Faulkner H.C., and Farmen R.H. The disposition of carboplatin in the beagle dog. Cancer Chemotherapy and Pharmacology 21 (1988) 197-2002
8. Gridelli C., Rossi A., Mongillo F., Bareschino M., Maione P., and Ciardiello F. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advamced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clinical Lung Cancer 8 (2007) 396-398
9. Hartung G. Food for thought... on cell culture. ALTEX 24 (2007) 143-152
10. Heim M., Scharifi M., Zisowsky J., Jaehde U., Voliotis D., Seeber S., and Strumberg D. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16 (2005) 129-136
11. Huether A., Höpfner M., Baradari V., Schuppan D., and Scherübl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochemical Pharmacology 73 (2007) 1308-1317
12. Karhoff D., Sauer S., Schrader J., Arnold R., Fendrich V., Bartsch D.K., and Hörsch D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85 (2007) 45-53
13. Kim C.S., Kim J.M., Nam S.Y., Yang K.H., Jeong M., Kim H.S., Lim Y.K., Kim C.S., Jin Y.W., and Kim J. Low-dose of ionizing radiation enhances cell proliferation via transient ERK1/2 and p38 activation in normal human lung fibroblasts. Journal of Radiation Research 48 (2007) 407-415
14. Kim S., Yazici Y.D., Calzada G., Younes M.N., Jasser S.A., El-Nagger A.K., and Myers J.N. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular Cancer Therapeutics 6 (2007) 1785-1792
15. Korystov Y.N., Eliseeva N.A., Kublik L.N., and Narimanov A.A. The effects of low-dose irradiation on proliferation of mammalian cells in vitro. Radiation Research 146 (1996) 329-332
16. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., and Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 66 (2006) 11851-11858
17. Priester W.A., and Mc Kay F.W. The occurence of tumors in domestic animals. Journal of the National Cancer Institute Monographs 54 (1980) 1-210
18. Rahmani M., Davis E.M., Bauer C., Dent P., and Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukaemia cells involves down-regulation of Mcl-1through inhibition of translation. The Journal of Biological Chemistry 280 (2005) 35217-35227
19. Robson H., Meyer S., Shalet S.M., Anderson E., Roberts S., and Eden O.B. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Medical and Pediatric Oncology 39 (2002) 573-580
20. Simon D., Knebel J.W., Baumgartner W., Aufderheide M., Meyer-Lindenberg A., and Nolte I. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary obtained from dogs. American Journal of Veterinary Research 62 (2001) 1825-1830
21. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics 4 (2005) 677-685
22. Steeghs N., Nortier J.W., and Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumours: an update of recent developments. Annals of Surgery Oncology 14 (2007) 942-953
23. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs of Today 41 (2005) 773-784
24. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C.G., Schwartz B., Awada A., Voigtmann R., Scheulen M.E., and Seeber S. Phase I clinical and pharmacokinetic study of the Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Journal of Clinical Oncology 23 (2005) 965-972
25. Strumberg D., Clark J.W., Awada A., Moore M.J., Richly H., Hendlisz A., Hirte H.W., Eder J.P., Lenz H.J., and Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 (2007) 426-437
26. Van Oijen M.G., Medema R.H., Slootweg P.J., and Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. American Journal of Clinical Pathology 110 (1998) 24-31
27. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch B., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64 (2004) 7099-7109
28. Wolfesberger B., Walter I., Hoelzl C., Thalhammer J.G., and Egerbacher M. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Research in Veterinary Science 80 (2006) 308-316